Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements

Go back to Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements

Eli Lilly & Co. (LLY) Shares Slide After Missing Estimates

August 4, 2022 11:06 AM EDT

Eli Lilly & Co. (NYSE: LLY) shares are down Thursday following its second-quarter earnings report, which saw it miss analyst estimates.

The drugmaker reported earnings of $1.25 per share, $0.46 below the analyst estimate of $1.71, while revenue came in at $6.49 billion versus the consensus estimate of $6.85... More

Eli Lilly & Co. (LLY) Misses Q2 EPS by 46c, Revenue Misses

August 4, 2022 6:27 AM EDT

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $1.25, $0.46 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $6.49 billion versus the consensus estimate of $6.85 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2022 EPS of $7.90-$8.05, versus the... More